Germany's BioNTech Q2 revenue drops 60% on lower COVID-19 vaccine demand
BNTX•Outlook
- BioNTech lowers 2026 revenue guidance to €1.6–1.9 bln due to weaker COVID-19 vaccine demand
- Company expects majority of 2026 revenue in second half, mainly in Q3 with €613 mln BMS collaboration
- BioNTech lowers 2026 adjusted R&D expense guidance to €2.0–2.3 bln; SG&A guidance unchanged at €700–800 mln
Overview
- Germany biopharma firm's Q2 revenue fell sharply yr/yr on lower COVID-19 vaccine demand
- Q2 net loss and diluted loss per share widened significantly from prior year
- Company cut full-year 2026 revenue guidance due to softer COVID-19 vaccine demand and milestone timing
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | EUR 105.60 mln | ||
| Q2 Loss Per Share | EUR 3.24 | ||
| Q2 Net Loss | EUR 820.80 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell".
Result Drivers
- COVID-19 VACCINE DEMAND - Co said lower COVID-19 vaccine demand drove revenue decline in Q2
